Sniffing for SNPs

Perlegen leads the way in efforts to find genetic markers for disease prevention and treatment.

Using genetic variation to predict disease has proved more difficult than sequencing the human genome. Still, some undaunted companies claim their technologies can pinpoint the useful differences.

Earlier this year, Perlegen Sciences, a genomics company that Affymetrix spun off in 2000, received $30 million in private placement financing led by Maverick Capital, and partnered with several companies, including Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Pfizer, to perform genome-wide scans for clinical trials.

News Analysis

Ready or Not

Vive la Differentiation!

Shrinking Staffs

Double Attack

Bull’s-Eye?

Biotech Buys

» Sniffing for SNPs